Ofloksasin: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
||
Baris 105:
==Sejarah==
Obat ini pertama kali disetujui untuk dipasarkan di Jepang pada tahun 1985, untuk pemberian oral, dan Daiichi memasarkannya di sana dengan nama merek Tarvid.<ref name=Atarashi>{{cite web | vauthors = Atarashi S | work = Daiichi | url = http://www.infectweb.com/only/03_SpeFeature.pdf | title = Research and Development of Quinolones in Daiichi Sankyo Co., Ltd. | archive-url = https://web.archive.org/web/20161012025535/http://www.infectweb.com/only/03_SpeFeature.pdf | archive-date= 12 October 2016 | access-date = 25 August 2016 }}</ref> Daiichi, bekerja sama dengan [[Johnson & Johnson]], memperoleh persetujuan [[Badan Pengawas Obat dan Makanan Amerika Serikat|FDA]] pada bulan Desember 1990, dengan nama merek Floxin, diberi label untuk digunakan pada orang dewasa dengan infeksi saluran pernapasan bawah, infeksi kulit dan struktur kulit, infeksi saluran kemih, prostatitis, dan penyakit menular seksual.<ref>{{cite web | title = LEVAQUIN Ortho-McNeil Pharmaceutical, Inc. v. Lupin Pharmaceutical, Inc. C.A. No. 06-04999-GEB-TJB May 1, 2009 Memorandum Opinion| publisher = Fish & RichaRdson P.C. | url = http://www.fr.com/files/Uploads/attachments/memoranda/memorANDAQ209.pdf | work = memorANDA | date = April 2009 | archive-url = https://web.archive.org/web/20160827002405/http://www.fr.com/files/Uploads/attachments/memoranda/memorANDAQ209.pdf | archive-date = 2016-08-27 | page = VIII }} Cites {{cite patent | country = US | number = 4382892 | title = Benzoxazine derivatives | assign1 = Daiichi Pharmaceutical Co. Ltd. | inventor = Hayakawa I, Hiramitsu T, Tanaka Y | gdate = 10 May 1983 | url = https://www.google.com/patents/US4382892 }}</ref><ref name=Pink>{{cite web | work = The Pink Sheet | date = 7 January 1991 | url = https://pink.pharmamedtechbi.com/PS018598/JOHNSON-amp-JOHNSON-GOING-INTO-1991-WITH-AT-LEAST-FOUR-NEW-PRODUCT-LAUNCHES-FLOXIN-VASCOR-PROCRIT-AND-DURAGESIC-JampJ-LEADING-OFF-WITH-PROCRIT-VASCOR | title = Johnson & Johnson Going Into 1991 With At Least Four New Product Launches: Floxin, Vascor, Procrit And Duragesic; J&J Leading Off With Procrit, Vascor | archive-url = https://web.archive.org/web/20160826140408/https://pink.pharmamedtechbi.com/PS018598/JOHNSON-amp-JOHNSON-GOING-INTO-1991-WITH-AT-LEAST-FOUR-NEW-PRODUCT-LAUNCHES-FLOXIN-VASCOR-PROCRIT-AND-DURAGESIC-JampJ-LEADING-OFF-WITH-PROCRIT-VASCOR | archive-date = 26 August 2016 }}</ref> Pada tahun 1991, ia juga dipasarkan sebagai Tarvid oleh [[Hoechst]] di
Pasar ofloksasin dipandang sulit sejak diluncurkan; obat ini disetujui sebagai obat "1C", sebuah entitas molekuler baru dengan sedikit atau tanpa manfaat terapeutik dibandingkan terapi yang ada, dan
Pada tahun 1992, solusi intravena disetujui untuk dipasarkan,<ref>{{cite journal | vauthors = Flor SC, Rogge MC, Chow AT | title = Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers | journal = Antimicrobial Agents and Chemotherapy | volume = 37 | issue = 7 | pages = 1468–1472 | date = July 1993 | pmid = 8363378 | pmc = 187996 | doi = 10.1128/aac.37.7.1468 }}</ref>
|